Advancements in Antiviral Therapeutics: Strategies and Challenges in the Development of Drugs and Vaccines for Viral Diseases

Year : 2024 | Volume : 01 | Issue : 01 | Page : 32 36
    By

    Kaushiky Sharma,

  1. Scholar, Department of Biotechnology, Chaudhary Charan Singh University, Meerut, Uttar Pradesh, India

Abstract

Viral infections continue to pose a significant threat to global health, leading to high rates of illness, death, and economic burden. The constantly evolving nature of viruses, along with the rise of drug-resistant strains, underscores the need for continuous advancements in antiviral treatments. This review highlights the pivotal role of antiviral drugs and vaccines in mitigating the impact of viral infections, showcasing recent breakthroughs and exploring emerging technologies. Key advancements include the development of direct-acting antivirals (DAAs) targeting critical viral pathways, innovations in nanoparticle-based drug delivery systems, and transformative vaccine technologies like mRNA and vector-based platforms. Despite these strides, challenges such as drug resistance, accessibility disparities, vaccine hesitancy, and equitable distribution hinder optimal outcomes. Future directions in antiviral therapeutics emphasize the integration of artificial intelligence and bioinformatics for drug discovery, the promise of personalized therapies, and the potential of pan-viral therapeutics targeting broad-spectrum viral vulnerabilities. By addressing these challenges through interdisciplinary collaboration, the global community can achieve sustainable progress in combating viral diseases. This review aims to provide a comprehensive overview, inspiring continued innovation and strategic efforts in the field of antiviral therapeutics.

Keywords: Antiviral drugs, vaccine development, drug resistance, mRNA vaccines, pan-viral therapeutics.

[This article belongs to International Journal of Virus Studies ]

How to cite this article:
Kaushiky Sharma. Advancements in Antiviral Therapeutics: Strategies and Challenges in the Development of Drugs and Vaccines for Viral Diseases. International Journal of Virus Studies. 2024; 01(01):32-36.
How to cite this URL:
Kaushiky Sharma. Advancements in Antiviral Therapeutics: Strategies and Challenges in the Development of Drugs and Vaccines for Viral Diseases. International Journal of Virus Studies. 2024; 01(01):32-36. Available from: https://journals.stmjournals.com/ijvs/article=2024/view=147158


References

  1. Baral B, Mamale K, Gairola S, Chauhan C, Dey A, Kaundal RK. Infectious diseases and its global epidemiology. InNanostructured Drug Delivery Systems in Infectious Disease Treatment 2024 Jan 1 (pp. 1-24). Academic Press.
  2. Milgroom MG. Emerging Infectious Diseases. InBiology of Infectious Disease: From Molecules to Ecosystems 2023 Nov 26 (pp. 285-303). Cham: Springer International Publishing.
  3. Shanmuga Priya C, Shalini M, Sanjay M, Akshara VA, Hardha B, Senthil Kumar M. REVIEW ON VACCINES VARIOUS PRODUCTION, TRENDS, CHALLENGES AND EFFICACY. World. 2023;2(6).
  4. Kumari R, Sharma SD, Kumar A, Ende Z, Mishina M, Wang Y, Falls Z, Samudrala R, Pohl J, Knight PR, Sambhara S. Antiviral approaches against influenza virus. Clinical microbiology reviews. 2023 Mar 23;36(1):e00040-22.
  5. Wang H. Practical updates in clinical antiviral resistance testing. Journal of clinical microbiology. 2024 Aug 14;62(8):e00728-23.
  6. McNab F, Mayer-Barber K, Sher A, Wack A, O’garra A. Type I interferons in infectious disease. Nature Reviews Immunology. 2015 Feb;15(2):87-103.
  7. Andey T, Soni S, Modi S. Conventional vaccination methods: Inactivated and live attenuated vaccines. Advanced Vaccination Technologies for Infectious and Chronic Diseases. 2024 Jan 1:37-50.
  8. Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, Quandt J, Bidmon N, Ulges A, Baum A, Pascal KE. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021 Jul 22;595(7868):572-7.
  9. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. New England Journal of Medicine. 2022 Apr 14;386(15):1397-408.
  10. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nature reviews Drug discovery. 2018 Apr;17(4):261-79.
  11. Mackin SR, Sariol A, Diamond MS. Antibody‐mediated control mechanisms of viral infections. Immunological Reviews. 2024.
  12. Erbelding EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, Paules CI, Graham BS, Fauci AS. A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases. The Journal of infectious diseases. 2018 Jul 2;218(3):347-54.
  13. Perelson AS, Ribeiro RM. Modeling the within-host dynamics of HIV infection. BMC biology. 2013 Dec;11:1-0.
  14. Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines. 2021 Feb 16;9(2):160.
  15. So AD, Woo J. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis. bmj. 2020 Dec 15;371.
  16. Pei J, Zhavoronkov A, editors. Artificial intelligence for drug discovery and development. Frontiers Media SA; 2021 Nov 16.
  17. Roa-Linares VC, Escudero-Flórez M, Vicente-Manzanares M, Gallego-Gómez JC. Host cell targets for unconventional antivirals against RNA viruses. Viruses. 2023 Mar 17;15(3):776.
  18. Kumari R, Sharma SD, Kumar A, Ende Z, Mishina M, Wang Y, Falls Z, Samudrala R, Pohl J, Knight PR, Sambhara S. Antiviral approaches against influenza virus. Clinical microbiology reviews. 2023 Mar 23;36(1):e00040-22.
Regular Issue Subscription Review Article
Volume 01
Issue 01
Received 24/04/2024
Accepted 18/05/2024
Published 21/05/2024
529

Login


My IP

PlumX Metrics